Syros Pharmaceuticals, Inc. Common Stock
SYRS
SYRS was delisted on the 19th of March, 2025.
62 hedge funds and large institutions have $446M invested in Syros Pharmaceuticals, Inc. Common Stock in 2019 Q3 according to their latest regulatory filings, with 5 funds opening new positions, 25 increasing their positions, 16 reducing their positions, and 11 closing their positions.
11,908% more call options, than puts
Call options by funds: $1.56M | Put options by funds: $13K
56% more repeat investments, than reductions
Existing positions increased: 25 | Existing positions reduced: 16
50% more funds holding in top 10
Funds holding in top 10: 2 → 3 (+1)
39% more capital invested
Capital invested by funds: $321M → $446M (+$125M)
19.38% more ownership
Funds ownership: 82.12% → 101.5% (+19%)
9% less funds holding
Funds holding: 68 → 62 (-6)
55% less first-time investments, than exits
New positions opened: 5 | Existing positions closed: 11
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AVM
Arch Venture Management
Chicago,
Illinois
|
+$36.4M |
| 2 |
Sumitomo Mitsui Trust Group
Minato-Ku, Tokyo,
Japan
|
+$28.8M |
| 3 |
NAMA
Nikko Asset Management Americas
New York
|
+$15.5M |
| 4 |
RG
Redmile Group
San Francisco,
California
|
+$2.53M |
| 5 |
State Street
Boston,
Massachusetts
|
+$1.05M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Alyeska Investment Group
Chicago,
Illinois
|
-$3M |
| 2 |
FP
Flagship Pioneering
Cambridge,
Massachusetts
|
-$2.51M |
| 3 |
EC
EcoR1 Capital
San Francisco,
California
|
-$2.3M |
| 4 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$616K |
| 5 |
Los Angeles Capital Management
Los Angeles,
California
|
-$374K |
SYRS Hedge Fund Activity: Q3 2019 in Review
62 of the 4,575 institutional investors tracked by Wall St. Rank reported a position in Syros Pharmaceuticals, Inc. Common Stock (SYRS) for Q3 2019, worth a combined $446M — up 39% from $321M a quarter earlier.
Sellers outnumbered buyers: 11 funds closed out of SYRS and 5 opened new positions — a net loss of 6 holders — while 16 trimmed existing stakes and 25 added.
The largest buyer was Arch Venture Management, opening a new position worth an estimated $36.4M. The largest seller was Alyeska Investment Group, exiting entirely with an estimated $3M sold.
- 62 institutional investors held Syros Pharmaceuticals, Inc. Common Stock (SYRS) as of Q3 2019, down from 68 in Q2 2019.
- Funds reported $446M of Syros Pharmaceuticals, Inc. Common Stock stock for Q3 2019, up 39% quarter-over-quarter.
- 5 funds opened new Syros Pharmaceuticals, Inc. Common Stock positions in Q3 2019 and 11 closed out, a net change of -6 holders.
- The largest Syros Pharmaceuticals, Inc. Common Stock buyer in Q3 2019 was Arch Venture Management, an estimated $36.4M added.
- The largest Syros Pharmaceuticals, Inc. Common Stock seller in Q3 2019 was Alyeska Investment Group, an estimated $3M sold.
Based on aggregated 13F filings for Q3 2019.